Clinics in North Carolina
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What North Carolina law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.
North Carolina at a glance
- Pharmacy regulator
- North Carolina Board of Pharmacy
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async unclear
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Verified clinics serving North Carolina
No verified clinics serving North Carolina are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.
Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.
Run a pharmacy, clinic, or telehealth service? Apply for a listing.
Peptide access rules in North Carolina
Yes. A North Carolina resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a North Carolina-licensed prescriber, including by telemedicine; North Carolina has no general telehealth practice statute, and the North Carolina Medical Board's telemedicine position statement allows evaluation without an in-person visit when the technology is sufficient to meet the standard of care. A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy permitted by the North Carolina Board of Pharmacy; out-of-state pharmacies must register annually under G.S. 90-85.21A. The Board's pharmacy FAQ says compounding copies of approved tirzepatide products is no longer allowed and that FDA's grace period for 503A copies of semaglutide ended April 22, 2025. [1] [2] [3] [4] [5] [6] [8]
Compounded GLP-1 access in North Carolina
Any out-of-state pharmacy shipping compounded GLP-1s in must hold an annual G.S. 90-85.21A registration. [3] [5] [9]
Research use only sellers in North Carolina
The North Carolina Food, Drug, and Cosmetic Act (G.S. 106-120 and following) prohibits selling adulterated or misbranded drugs, and the Pharmacy Practice Act restricts dispensing of legend drugs to permitted pharmacies. [4] [7] [10]
North Carolina notes on specific peptides
- Semaglutide: Available branded by prescription, including by telemedicine from a North Carolina-licensed prescriber. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025, the date the North Carolina Board of Pharmacy's FAQ gives for the end of FDA's grace period for 503A pharmacies. [6] [9]
How to check a clinic in North Carolina
- Confirm the prescribing clinician's license with the North Carolina medical or nursing board.
- Ask which pharmacy compounds or dispenses the peptide and check it in the North Carolina Board of Pharmacy license lookup. [1] [3] [4] [5] [6] [8]
- Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in North Carolina. [4] [7] [10]
Common questions in North Carolina
Can I get a GLP-1 prescription in North Carolina through telemedicine?
Yes, from a North Carolina-licensed prescriber. The North Carolina Medical Board's telemedicine position says an evaluation need not be in person if the technology is sufficient to diagnose and treat under the standard of care, and semaglutide and tirzepatide are not controlled substances. [2]
Sources
- [1]North Carolina Board of Pharmacy
- [2]North Carolina Medical Board Position Statement 5.1.4, Telemedicine
- [3]N.C. G.S. 90-85.21A, Pharmacies outside North Carolina (nonresident registration)
- [4]N.C. G.S. Chapter 90, Article 4A, North Carolina Pharmacy Practice Act
- [6]North Carolina Board of Pharmacy: General pharmacy FAQs (compounding GLP-1s and semaglutide)
- [7]N.C. G.S. Chapter 106, Article 12, Food, Drug, and Cosmetic Act
- [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [10]21 U.S.C. 331, Prohibited acts